Partial Response to Entecavir and Tenofovir in Naïve Patients with Chronic Hepatitis B: Clinical Relevance and Management
- 162 Downloads
Entecavir and tenofovir are the currently recommended first line analogues for treatment of naïve patients with chronic hepatitis B. Despite their overall efficacy and high genetic barrier granting for a low risk of resistance, both regimens will fail to completely suppress HBV DNA at week 48 in 10% of HBeAg-negative and 30% of HBeAg-positive patients. A pre-treatment level >8 log10 IU/mL HBV DNA and poor medication adherence were the most significant predictors of a partial virological response (PVR). While the clinical relevance of PVR is still poorly understood, nucleos(t)ide (NUC)-naive PVR patients who maintained detectable levels of viremia in follow up, were at risk of developing resistance to ETV. Patients with a suboptimal decline of viremia during the first 48 weeks of therapy with ETV and/or a residual viremia >1,000 IU/mL, can be protected by a rescue switch to TDF. Resistance to TDF has not been described so far, yet the long-term risk of PVR in TDF-treated patients remains unclear.
KeywordsHBV infection Chronic hepatitis Antiviral treatment Entecavir Tenofovir Drug resistance Rescue therapy Add-on strategy Long-term treatment Clinical resistance
Dr. M. Colombo has received grant support from Merck, Roche, BMS, and Gilead Science, payment for development of educational presentations and travel and accommodation reimbursement from Tibotec, Roche, Novartis, Bayer, BMS, Gilead Science and Vertex; Dr. P. Lampertico has received payment for development of educational presentations and travel and accommodation reimbursement from GSK, Gilead, BMS, and Roche; Dr. M. Viganò reported no potential conflicts of interest relevant to this article.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 7.• Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503–14. In this long-term study in NUCs-naïve patients treated with ETV, the 5-year cumulative probability of genotypic ETV-resistance was 1.2%.PubMedCrossRefGoogle Scholar
- 9.• Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54:91–100. This randomized, open-label comparative study in subjects with CHB and hepatic decompensation showed that patients treated with ETV had a higher rate of undetectable serum HBV DNA at weeks 48 compared to those treated with ADV.PubMedCrossRefGoogle Scholar
- 10.Lampertico P, Viganò M, Facchetti F, et al. Effectiveness and safety of entecavir treatment of nucleos(t)ide-naïve chronic hepatitis B patients: a 4-year multicenter field practice study of 418 patients in Italy. (submitted)Google Scholar
- 11.•• Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology. 2011;54:443–51. This study showed that ETV monotherapy can be continued in NUCs-naïve patients with detectable HBV DNA at week 48, particularly in those with a viral load <1,000 IU/mL because long-term ETV leads to a virological response in the vast majority of those patients.PubMedCrossRefGoogle Scholar
- 13.Lok AS, Trinh HN, Carosi G, et al. Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide-naive patients with chronic hepatitis B (CHB): the below study. Hepatology. 2011;54:471A.Google Scholar
- 20.•• Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–55. In this large multinational trial in chronic hepatitis B patients, TDF at a daily dose of 300 mg had superior antiviral efficacy with a similar safety profile as compared with ADV at a daily dose of 10 mg through week 48.PubMedCrossRefGoogle Scholar
- 21.Marcellin P, Heathcote EJ, Corsa A, et al. No detectable resistance to tenofovir disoproxil fumarate (TDF) following 240 weeks of treatment in patients with HBeAg + and HBeAg- chronic hepatitis B virus infection. Hepatology. 2011;54:480A.Google Scholar
- 24.Carey I, Nguyen HL, Joe D, et al. De-novo antiviral therapy with nucleos(t)ide analogues in “real-life” patients with chronic hepatitis B infection: comparison of virological response between lamivudine + adefovir vs entecavir vs tenofovir therapy. Hepatology. 2011;54:1022A.Google Scholar
- 25.Pan C, Hu K, Yu AS, et al. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hep 2011, in pressGoogle Scholar